Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18

Insight Molecular Diagnostics Inc.

Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.
Stock ticker changes from OCX to IMDX, effective before market open on June 18, 2025.
Principal executive office relocated from Irvine, CA to Nashville, TN; CLIA lab already in Nashville.
Product rebranding: VitaGraft Kidney (LDT) → GraftAssureCore, RUO kit → GraftAssureIQ, future IVD kit → GraftAssureDx.
CEO letter reports progress toward FDA submission of transplant rejection test kit; three top-10 US transplant centers engaged.

item 5.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.